CBLL · CeriBell, Inc.

The thesis

CeriBell launched its delirium monitor on 2 November 2026, and third-quarter usage per account grew at its fastest pace since the initial public offering (IPO), so the launch risk has given way to a size question. The case now depends on 2027 revenue guidance, which management says will give "a more granular perspective" on delirium's revenue impact.

The narrative is maturing: the Medicare payment has been public since 3 August 2026, and the 3 November 2026 report moved the story from a pilot to a sold product without a usage figure attached. The Centers for Medicare & Medicaid Services (CMS) pays hospitals a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible case, effective 1 October 2026 (CeriBell's NTAP announcement). The evidence so far favors the case modestly, because core usage is strong while costs are still growing faster than sales.

Bullish and bearish views on CeriBell, Inc.

The bull case on CeriBell, Inc. (CBLL), in brief: Launch arrived inside the expected window. The bear case: The second quarter showed the same pattern, at 37% against 33%.

Bull case

• Launch arrived inside the expected window. CeriBell announced the commercial launch on 2 November 2026 (company news). That resolves the timing risk in the 22 October 2026 note, which set 31 December 2026 as the latest acceptable date.
• Pilot customers used more headbands. CEO Jane Chao cited a "material increase in headband utilization" at pilot sites on the 3 November 2026 call (transcript). The gains lasted at least 120 days at the earliest customers and appeared before the payment began.
• Core business is gaining accounts. Third-quarter revenue was $29.3 million, up 30% year over year, with 747 active accounts after a record 35 net additions (3 November 2026 results). Chao said usage per account grew at a double-digit rate, the highest since the IPO.
• Guidance leaves delirium out. The full-year 2026 revenue range rose to $115 million–$117 million from $114 million–$117 million on 3 November 2026. It excludes material contributions from delirium, neonate and pediatric products.
• Analyst targets moved up. Canaccord Genuity raised its target to $33 and BofA Securities raised its target to $31 from $26 on 4 November 2026 (company news). TD Cowen's target was $33 on 2 October 2026 (Benzinga).

Bear case

• The second quarter showed the same pattern, at 37% against 33%.
• Losses widened year over year. The third-quarter net loss was $21.4 million, or $0.55 per share, against a $0.51 loss estimate (Benzinga, 3 November 2026). Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was a $12.1 million loss, compared with a $9.2 million loss a year earlier.
• Margin is guided lower. Gross margin was 90% in the third quarter, after 92% in the second, which included a one-time tariff refund. CFO Scott Blumberg said on 3 November 2026 that CeriBell expects margins "in the high 80% range going forward," on current tariff policy and inventory.
• Delirium carries no new fee. It ships as a software upgrade with no subscription increase and no minimum volume commitment, per the 3 November 2026 call. Revenue therefore depends entirely on hospitals using more headbands, and Chao said it is "a bit too early" to quantify the lift.
• Revenue growth slowed. Growth eased to 30% in the third quarter from 33% in the second, and the top of the 2026 revenue range did not move. Blumberg also said headband purchases lagged usage slightly in the quarter.

Price setup

The adjusted close on 5 November 2026 was $26.01, 8.0% below the 52-week high of $28.27. The shares closed at $27.14 on 21 October 2026 and at $23.15 on 8 October 2026, and they are up 34.8% over three months.

Crowding signs are modest. The 14-day relative strength index (RSI), a momentum gauge, stands at 55.0, compared with 63.3 at the 21 October 2026 close. The earnings date has passed, and the August 2026 financing was debt: $60 million committed, split between a $30 million term loan and a $30 million revolver. Published targets of $30 to $33 from BTIG, BofA, Canaccord and TD Cowen all sit above the last close, with BTIG's dating from 18 August 2026.

Catalysts, next 30 days

• By 31 December 2026: Management plans to begin a limited market release of its Omni hardware platform this quarter, with the full launch in 2027.
• ~25 February 2027, est.: The fourth-quarter report and 2027 guidance fall outside the 30-day window, but the case turns on them. This is the first scheduled point for a delirium revenue figure.

Elapsed catalysts

• Date not confirmed: CeriBell's CFO is due at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, per company news on 28 October 2026. Any delirium usage comment would be the first since the launch call. (passed 9d ago)

What would change the view

The case breaks if 2027 guidance gives no measurable delirium contribution, or if usage per account falls back below double-digit growth while the launch rolls out. Delirium is an unpaid upgrade, so flat headband revenue at launched accounts would mean the payment is not changing hospital behavior.

A further break would be operating expenses again growing faster than revenue in 2027 guidance after management said on 3 November 2026 that infrastructure investments are "largely made." Gross margin below the high-80% range would also weaken the case.

On price, a weekly close below $23.00 would end the view, because it would fall under the 8 October 2026 close of $23.15 where the October advance began. A disclosed usage lift at launched accounts, with product revenue growth above the 31% reported for the third quarter, would strengthen it.

What it trades with

The shares follow company-specific events more than any sector measure in the evidence reviewed: the payment approval, the launch and the quarterly usage figures. Three outside inputs reach the business directly. CMS sets the add-on payment, tariff policy shapes the margin outlook by management's own account, and Veterans Affairs (VA) orders roll into accounts over two to three quarters. As a loss-making company with $117.5 million of cash and securities on 30 September 2026, CeriBell also carries funding sensitivity that profitable medical-device peers do not. A cash-flow breakeven reached on cash on hand, management's stated objective, would remove that sensitivity.